Oral GLP-1 Drugs May Reduce Pleasure Eating by Modulating Brain Reward System

Research conducted in mice suggests that new oral GLP-1 medications, similar to semaglutide, might decrease pleasure-driven eating. The study indicates these drugs achieve this effect by influencing a specific reward circuit deep within the brain. This discovery reveals a novel mechanism of action for GLP-1 drugs and could inform future treatments for food cravings and potentially substance use disorders.